xemilofiban has been researched along with Thrombopenia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boersma, E; Brugts, JJ; Guarneri, M; Hu, S; Mercado, N; O'Neill, WW; Price, M; Schatz, R; Serruys, PW; Teirstein, P; Wijns, W | 1 |
| Abrams, CS; Cines, DB | 1 |
| Aster, RH; Brassard, JA; Cannon, CP; Cooper, RA; Curtis, BR; Ehardt, M; Ferguson, J; Komocsar, W; Kupfer, S; Maurath, C; Swabb, E | 1 |
| Alexander, J; Anders, R; Dreiling, R; Gong, J; Kleiman, J; Knudtson, M; O'Neill, WW; Roecker, EB; Serruys, P; Timmis, GC; van der Zwaan, C; van Es, GA | 1 |
| Jang, IK; Sabatine, MS | 1 |
2 review(s) available for xemilofiban and Thrombopenia
| Article | Year |
|---|---|
Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis.
Topics: Abciximab; Alanine; Antibodies, Monoclonal; Autoimmunity; Benzamidines; Humans; Immunoglobulin Fab Fragments; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Pyrrolidines; Thrombocytopenia; Thrombosis | 2002 |
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
3 trial(s) available for xemilofiban and Thrombopenia
| Article | Year |
|---|---|
Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial).
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Benzamidines; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Preoperative Care; Risk Factors; Survival Rate; Thrombocytopenia; Time Factors; Treatment Outcome; United States | 2009 |
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology.
Topics: Acute Disease; Alanine; Autoantibodies; Autoimmunity; Benzamidines; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Pyrrolidines; Risk Factors; Thrombocytopenia | 2002 |
Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Benzamidines; Coronary Artery Bypass; Coronary Disease; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Thrombocytopenia | 2000 |